Intersect ENT Inc. (XENT)

21.18
NASDAQ : Health Technology
Prev Close 20.80
Day Low/High 20.86 / 21.46
52 Wk Low/High 14.62 / 35.87
Avg Volume 384.30K
Exchange NASDAQ
Shares Outstanding 31.52M
Market Cap 655.51M
EPS -0.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

XENT Alert: Johnson Fistel Investigates Intersect ENT, Inc.; Should Management Be Held Accountable For Investors Losses?

XENT Alert: Johnson Fistel Investigates Intersect ENT, Inc.; Should Management Be Held Accountable For Investors Losses?

SAN DIEGO, Oct. 7, 2019 /PRNewswire/ -- Johnson Fistel, LLP is investigating potential claims on behalf of Intersect ENT, Inc.

Intersect ENT Announces Results From The ASCEND Study Of Company's Investigational Drug-Coated Balloon For Sinus Dilation

Intersect ENT Announces Results From The ASCEND Study Of Company's Investigational Drug-Coated Balloon For Sinus Dilation

Intersect ENT®, Inc. (NASDAQ: XENT), a company dedicated to transforming care for patients with ear, nose and throat conditions, today announced results from a study of the company's ASCEND investigational drug-coated sinus balloon.

Shareholder Alert: Robbins Arroyo LLP Reminds Investors Intersect ENT, Inc. (XENT) Sued For Misleading Shareholders

Shareholder Alert: Robbins Arroyo LLP Reminds Investors Intersect ENT, Inc. (XENT) Sued For Misleading Shareholders

Shareholder rights law firm Robbins Arroyo LLP reminds investors that a purchaser of Intersect ENT, Inc.

Intersect ENT Is Now Oversold (XENT)

Intersect ENT Is Now Oversold (XENT)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Noteworthy Monday Option Activity: XENT, CWEN, OPRX

Noteworthy Monday Option Activity: XENT, CWEN, OPRX

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Intersect ENT, Inc. , where a total of 4,180 contracts have traded so far, representing approximately 418,000 underlying shares.

Intersect ENT Reports Second Quarter 2019 Results

Intersect ENT Reports Second Quarter 2019 Results

Intersect ENT, Inc. (NASDAQ:XENT), a company dedicated to transforming care for patients with ear, nose and throat conditions, today reported financial results for the second quarter ended June 30, 2019.

Intersect ENT Announces FDA Approval Of New PROPEL Mini Straight Delivery System

Intersect ENT Announces FDA Approval Of New PROPEL Mini Straight Delivery System

Intersect ENT ®, Inc. (Nasdaq:XENT), a company dedicated to transforming care for patients with ear, nose and throat conditions, today announced that the company has received approval from the U.

Intersect ENT To Report Second Quarter 2019 Financial Results

Intersect ENT To Report Second Quarter 2019 Financial Results

Intersect ENT, Inc. (NASDAQ: XENT), a company dedicated to transforming care for patients with ear, nose and throat conditions, today announced that it will release second quarter financial results on August 1, 2019.

First Week Of XENT August 16th Options Trading

First Week Of XENT August 16th Options Trading

Investors in Intersect ENT, Inc. saw new options become available this week, for the August 16th expiration.

Intersect ENT Announces Appointment Of Thomas A. West As CEO

Intersect ENT Announces Appointment Of Thomas A. West As CEO

Intersect ENT ®, Inc. (Nasdaq:XENT), a company dedicated to transforming care for patients with ear, nose and throat conditions, today announced the appointment of Thomas ("Tom") A.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Intersect ENT, Inc. - XENT

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Intersect ENT, Inc. - XENT

NEW YORK, June 20, 2019 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Intersect ENT, Inc.

Intersect ENT Announces Publication Of A Pooled Analysis Of The SINUVA Sinus Implant For Nasal Polyps

Intersect ENT Announces Publication Of A Pooled Analysis Of The SINUVA Sinus Implant For Nasal Polyps

Intersect ENT ®, Inc. (NASDAQ: XENT), a company dedicated to transforming care for patients with ear, nose and throat conditions, today announced publication of a pooled analysis of the RESOLVE and RESOLVE II randomized controlled trials (RCT) in the...

LEAD PLAINTIFF DEADLINE: Johnson Fistel, LLP Encourages Investors Who Suffered Large Investment Losses To Contact The Firm

LEAD PLAINTIFF DEADLINE: Johnson Fistel, LLP Encourages Investors Who Suffered Large Investment Losses To Contact The Firm

SAN DIEGO, June 1, 2019 /PRNewswire/ -- Johnson Fistel, LLP announces that class action lawsuits have been commenced on behalf of shareholders of the publicly-traded companies listed below.

Rosen, A Globally Recognized Law Firm, Announces Filing Of Securities Class Action Lawsuit Against Intersect ENT, Inc. - XENT

Rosen, A Globally Recognized Law Firm, Announces Filing Of Securities Class Action Lawsuit Against Intersect ENT, Inc. - XENT

NEW YORK, May 30, 2019 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Intersect ENT, Inc.

Robbins Arroyo LLP: Intersect ENT, Inc. (XENT) Misled Shareholders According To A Recently Filed Lawsuit

Robbins Arroyo LLP: Intersect ENT, Inc. (XENT) Misled Shareholders According To A Recently Filed Lawsuit

Shareholder rights law firm Robbins Arroyo LLP announces that a purchaser of Intersect ENT, Inc.

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Intersect ENT, Inc. To Contact The Firm

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Intersect ENT, Inc. To Contact The Firm

NEW YORK, May 23, 2019 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Intersect ENT, Inc.

Deadline Reminder: The Law Offices Of Howard G. Smith Reminds Investors Of Looming Deadline In The Class Action Lawsuit Against Intersect ENT, Inc.

Deadline Reminder: The Law Offices Of Howard G. Smith Reminds Investors Of Looming Deadline In The Class Action Lawsuit Against Intersect ENT, Inc.

Law Offices of Howard G. Smith reminds investors of the upcoming  July 15, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Intersect ENT, Inc.

INTERSECT DEADLINE REMINDER: Rosen Law Firm Reminds Intersect ENT, Inc. Investors Of The Important Lead Plaintiff Deadline In Securities Class Action; Encourages Investors With Losses In Excess Of $100K To Contact The Firm

INTERSECT DEADLINE REMINDER: Rosen Law Firm Reminds Intersect ENT, Inc. Investors Of The Important Lead Plaintiff Deadline In Securities Class Action; Encourages Investors With Losses In Excess Of $100K To Contact The Firm

Rosen Law Firm, a global investor rights law firm, reminds Intersect ENT, Inc. (NASDAQ:XENT) from August 1, 2018 through May 6, 2019, inclusive (the "Class Period") of the important July 15, 2019 lead plaintiff deadline in the securities class action.

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Intersect ENT, Inc. To Contact The Firm

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Intersect ENT, Inc. To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Intersect ENT, Inc.

Scott Scott Attorneys At Law LLP Announces The Filing Of A Securities Class Action Against Intersect ENT, Inc. (XENT)

Scott Scott Attorneys At Law LLP Announces The Filing Of A Securities Class Action Against Intersect ENT, Inc. (XENT)

Scott+Scott Attorneys at Law LLP ("Scott+Scott"), an international shareholder and consumer rights litigation firm, is notifying investors that a securities class action lawsuit has been filed against Intersect ENT, Inc.

EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against Intersect ENT, Inc.

EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against Intersect ENT, Inc.

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Intersect ENT, Inc.

Glancy Prongay & Murray LLP Announces Investigation On Behalf Of Intersect ENT, Inc. Investors

Glancy Prongay & Murray LLP Announces Investigation On Behalf Of Intersect ENT, Inc. Investors

Glancy Prongay & Murray LLP ("GPM") announces an investigation on behalf of Intersect ENT, Inc.

SHAREHOLDER ALERT: Investigation Of Intersect ENT Announced By Holzer & Holzer, LLC

SHAREHOLDER ALERT: Investigation Of Intersect ENT Announced By Holzer & Holzer, LLC

Holzer & Holzer, LLC is investigating whether certain statements made by Intersect ENT, Inc.

Intersect ENT Reports First Quarter 2019 Results

Intersect ENT Reports First Quarter 2019 Results

Intersect ENT ® , Inc. (NASDAQ:XENT), a company dedicated to transforming care for patients with ear, nose and throat conditions, today reported financial results for the first quarter ended March 31, 2019.

Intersect ENT Announces CEO Transition Plan

Intersect ENT Announces CEO Transition Plan

Intersect ENT ® , Inc. (Nasdaq: XENT), a company dedicated to transforming care for patients with ear, nose and throat conditions, today announced that Lisa Earnhardt will be stepping down from her role as Chief Executive Officer on June 5, 2019 to accept...

Intersect ENT To Present At The Bank Of America Merrill Lynch 2019 Health Care Conference

Intersect ENT To Present At The Bank Of America Merrill Lynch 2019 Health Care Conference

Intersect ENT, Inc. (Nasdaq: XENT) today announced that management will participate in the 2019 Bank of America Merrill Lynch Health Care Conference on Tuesday, May 14, 2019 at the Encore Hotel in Las Vegas, including a Q&A session at 1:40 p.

Intersect ENT To Report First Quarter 2019 Financial Results

Intersect ENT To Report First Quarter 2019 Financial Results

Intersect ENT, Inc. (NASDAQ: XENT), a company dedicated to transforming care for patients with ear, nose and throat conditions, today announced that it will release first quarter financial results on May 6, 2019.

TheStreet Quant Rating: D (Sell)